144 related articles for article (PubMed ID: 37932157)
1. Evaluation of a miRNA-371a-3p Assay for Predicting Final Histopathology in Patients Undergoing Primary Nerve-sparing Retroperitoneal Lymphadenectomy for Stage IIA/B Seminoma or Nonseminoma.
Seelemeyer F; Pfister D; Pappesch R; Merkelbach-Bruse S; Paffenholz P; Heidenreich A
Eur Urol Oncol; 2024 Jun; 7(3):319-322. PubMed ID: 37932157
[TBL] [Abstract][Full Text] [Related]
2. Retroperitoneal Lymph Node Dissection in Clinical Stage IIA/B Metastatic Seminoma: Results of the COlogne Trial of Retroperitoneal Lymphadenectomy In Metastatic Seminoma (COTRIMS).
Heidenreich A; Paffenholz P; Hartmann F; Seelemeyer F; Pfister D
Eur Urol Oncol; 2024 Feb; 7(1):122-127. PubMed ID: 37438222
[TBL] [Abstract][Full Text] [Related]
3. Serum Levels of MicroRNA-371a-3p (M371 Test) as a New Biomarker of Testicular Germ Cell Tumors: Results of a Prospective Multicentric Study.
Dieckmann KP; Radtke A; Geczi L; Matthies C; Anheuser P; Eckardt U; Sommer J; Zengerling F; Trenti E; Pichler R; Belz H; Zastrow S; Winter A; Melchior S; Hammel J; Kranz J; Bolten M; Krege S; Haben B; Loidl W; Ruf CG; Heinzelbecker J; Heidenreich A; Cremers JF; Oing C; Hermanns T; Fankhauser CD; Gillessen S; Reichegger H; Cathomas R; Pichler M; Hentrich M; Eredics K; Lorch A; Wülfing C; Peine S; Wosniok W; Bokemeyer C; Belge G
J Clin Oncol; 2019 Jun; 37(16):1412-1423. PubMed ID: 30875280
[TBL] [Abstract][Full Text] [Related]
4. Post-chemotherapy laparoscopic retroperitoneal lymph node dissection is feasible for stage IIA/B non-seminoma germ cell tumors.
Nakamura T; Kawauchi A; Oishi M; Ueda T; Shiraishi T; Nakanishi H; Kamoi K; Naya Y; Hongo F; Okihara K; Miki T
Int J Clin Oncol; 2016 Aug; 21(4):791-795. PubMed ID: 26701172
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of miR-371a-3p to predict viable germ cell tumor in patients with pure seminoma receiving retroperitoneal lymph node dissection.
Konneh B; Lafin JT; Howard J; Gerald T; Amini A; Savelyeva A; Woldu SL; Lewis CM; Jia L; Margulis V; Coleman N; Scarpini C; Frazier AL; Murray MJ; Amatruda JF; Bagrodia A
Andrology; 2023 May; 11(4):634-640. PubMed ID: 36254623
[TBL] [Abstract][Full Text] [Related]
6. Retroperitoneal Lymph Node Dissection as Primary Treatment for Men With Testicular Seminoma: Utilization and Survival Analysis Using the National Cancer Data Base, 2004-2014.
Tabakin AL; Shinder BM; Kim S; Rivera-Nunez Z; Polotti CF; Modi PK; Sterling JA; Farber NJ; Radadia KD; Parikh RR; Kim IY; Saraiya B; Mayer TM; Singer EA; Jang TL
Clin Genitourin Cancer; 2020 Apr; 18(2):e194-e201. PubMed ID: 31818649
[TBL] [Abstract][Full Text] [Related]
7. [Positron emission tomography with [18 F]-2-fluoro-2-deoxy-D-glucose (18FDG-PET) in diagnosis of retroperitoneal lymph node metastases of testicular tumors].
Müller-Mattheis V; Reinhardt M; Gerharz CD; Fürst G; Vosberg H; Müller-Gärtner HW; Ackermann R
Urologe A; 1998 Nov; 37(6):609-20. PubMed ID: 9887489
[TBL] [Abstract][Full Text] [Related]
8. Serum miRNA Predicts Viable Disease after Chemotherapy in Patients with Testicular Nonseminoma Germ Cell Tumor.
Leão R; van Agthoven T; Figueiredo A; Jewett MAS; Fadaak K; Sweet J; Ahmad AE; Anson-Cartwright L; Chung P; Hansen A; Warde P; Castelo-Branco P; O'Malley M; Bedard PL; Looijenga LHJ; Hamilton RJ
J Urol; 2018 Jul; 200(1):126-135. PubMed ID: 29474847
[TBL] [Abstract][Full Text] [Related]
9. Complications of primary nerve sparing retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell tumors of the testis: experience of the German Testicular Cancer Study Group.
Heidenreich A; Albers P; Hartmann M; Kliesch S; Kohrmann KU; Krege S; Lossin P; Weissbach L;
J Urol; 2003 May; 169(5):1710-4. PubMed ID: 12686815
[TBL] [Abstract][Full Text] [Related]
10. Current controversies on the role of retroperitoneal lymphadenectomy for testicular cancer.
Mano R; Di Natale R; Sheinfeld J
Urol Oncol; 2019 Mar; 37(3):209-218. PubMed ID: 30446455
[TBL] [Abstract][Full Text] [Related]
11. Serum Levels of MicroRNA371a-3p: A Highly Sensitive Tool for Diagnosing and Staging Testicular Germ Cell Tumours: A Clinical Case Series.
Anheuser P; Radtke A; Wülfing C; Kranz J; Belge G; Dieckmann KP
Urol Int; 2017; 99(1):98-103. PubMed ID: 28586780
[TBL] [Abstract][Full Text] [Related]
12. [Reduced retroperitoneal lymphadenectomy for clinical stage I non seminomatous germ cell testicular cancer].
Valdevenito Sepúlveda JP; Merhe Nieva E; Valdevenito Sepúlveda R; Cuevas Toro M; Gómez Gallo A; Bermúdez Luna H; Contreras Meléndez L; Gallegos Méndez I; Gallardo Escobar J; Palma Ceppi C
Arch Esp Urol; 2007 Apr; 60(3):245-54. PubMed ID: 17601299
[TBL] [Abstract][Full Text] [Related]
13. Primary Retroperitoneal Lymph Node Dissection for Seminoma Metastatic to the Retroperitoneum.
Matulewicz RS; Benfante N; Funt SA; Feldman DR; Carver B; Doudt A; Knezevic A; Sheinfeld J
J Urol; 2024 Jan; 211(1):80-89. PubMed ID: 37672753
[TBL] [Abstract][Full Text] [Related]
14. Is routine primary retroperitoneal lymph node dissection still justified in patients with low stage non-seminomatous testicular cancer?
Aass N; Fosså SD; Ous S; Lien HH; Stenwig AE; Paus E; Kaalhus O
Br J Urol; 1990 Apr; 65(4):385-90. PubMed ID: 2340372
[TBL] [Abstract][Full Text] [Related]
15. Radiomics allows for detection of benign and malignant histopathology in patients with metastatic testicular germ cell tumors prior to post-chemotherapy retroperitoneal lymph node dissection.
Baessler B; Nestler T; Pinto Dos Santos D; Paffenholz P; Zeuch V; Pfister D; Maintz D; Heidenreich A
Eur Radiol; 2020 Apr; 30(4):2334-2345. PubMed ID: 31828413
[TBL] [Abstract][Full Text] [Related]
16. Incidence of disease outside modified retroperitoneal lymph node dissection templates in clinical stage I or IIA nonseminomatous germ cell testicular cancer.
Eggener SE; Carver BS; Sharp DS; Motzer RJ; Bosl GJ; Sheinfeld J
J Urol; 2007 Mar; 177(3):937-42; discussion 942-3. PubMed ID: 17296380
[TBL] [Abstract][Full Text] [Related]
17. Primary retroperitoneal lymph node dissection in low-stage testicular germ cell tumors: a detailed pathologic study with clinical outcome analysis with special emphasis on patients who did not receive adjuvant therapy.
Al-Ahmadie HA; Carver BS; Cronin AM; Olgac S; Tickoo SK; Fine SW; Gopalan A; Stasi J; Rabbani F; Bosl GJ; Sheinfeld J; Reuter VE
Urology; 2013 Dec; 82(6):1341-6. PubMed ID: 24094656
[TBL] [Abstract][Full Text] [Related]
18. Outcomes of post-chemotherapy robot-assisted retroperitoneal lymph node dissection in testicular cancer: multi-institutional study.
Abdul-Muhsin H; Rocco N; Navaratnam A; Woods M; L'Esperance J; Castle E; Stroup S
World J Urol; 2021 Oct; 39(10):3833-3838. PubMed ID: 33959785
[TBL] [Abstract][Full Text] [Related]
19. [When is surgical resection of metastases in testicular germ cell tumors indicated and is there a scientific basis?].
Heidenreich A; Paffenholz P; Haidl F; Pfister D
Urologe A; 2017 May; 56(5):627-636. PubMed ID: 28432399
[TBL] [Abstract][Full Text] [Related]
20. Re: Felix Seelemeyer, David Pfister, Robert Pappesch, et al. Evaluation of a miRNA-371a-3p Assay for Predicting Final Histopathology in Patients Undergoing Primary Nerve-sparing Retroperitoneal Lymphadenectomy for Stage IIA/B Seminoma or Nonseminoma. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2023.10.021.
Urabe F; Yoshioka T; Kimura T
Eur Urol Oncol; 2024 Apr; 7(2):307. PubMed ID: 38238224
[No Abstract] [Full Text] [Related]
[Next] [New Search]
